# US 2009/0276160 A1 · Crystal structure of hepatocyte growth factor activator complexed with kunitz domain inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0276160 A1
- Document ID: US20090276160A1
- Status: Published application
- Kind: A1
- Application number: 11/721,012
- Filed: 2005-12-09
- Published: 2009-11-05
- Earliest claimed: 2004-12-10
- Assignees: Genentech, Inc.
- Inventors: Charles E. EIGENBROT, Jr.
- Web page: https://patentgrep.com/patent/US20090276160A1

## CPC

- C12N 9/6424: {Serine endopeptidases (3.4.21)}
- C07K 14/4753: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides crystals of and structural coordinates of Hepatocyte growth factor activator with and without bound pseudo-substrate or inhibitor. In a specific embodiment, a crystal structure of activated HGFA complexed with a Kunitz domain inhibitor is provided. The crystals and crystal structures are useful, for example, in the design and synthesis of inhibitors of HGFA.

## Claims

### Claim 1

A crystal comprising a human hepatocyte growth factor activator (HGFA) comprising SEQ ID NO:1, or a fragment of SEQ ID NO:1 comprising the sequence of amino acids 373 to 655 of SEQ ID NO:1.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

A crystal of a fragment of HGFA of claim 1 having a space group symmetry of P21 and comprising a unit cell having the dimensions of a is about 52.53 Å, b is about 76.43 Å, and c is about 72.15 Å.

### Claim 4 (depends on 1)

A crystal of HGFA of claim 1 having the three dimensional coordinates of Table 7.

### Claim 5 (depends on 1)

A composition comprising a crystal of claim 1, and a carrier.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the HGFA has at least one biological activity when resolubilized.

### Claim 7 (depends on 1)

A heavy atom derivative of a crystallized form of HGFA of claim 1.

### Claim 8 (depends on 1)

A crystal of claim 1, wherein the HGFA is activated.

### Claim 9

(canceled)

### Claim 10

A molecule or molecular complex comprising at least a portion of an unbound HGFA binding site of a polypeptide having an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2, wherein the binding site comprises at least one amino acid residue corresponding to an amino acid residue in a position of HGFA selected from the group consisting of 489(95), 537(138), 559(160), 573(172), 576(175), 577(176), 581(180), 591(188), 592 (189), 593(190), 616(213), 617(214), 618(215), 619(216), 620(217), 621(219), 622(220), 626(223), 627(224), 628(225), 629(226), 630(227), 631(228), and mixtures thereof, and the at least one amino acid residue is defined by a set of points having a root mean square deviation of less than about 0.70 Å from points representing the backbone atoms of the amino acids as represented by the structure coordinates listed in Table 7.

### Claim 11

(canceled)

### Claim 12

A three-dimensional configuration of points displayed as a holographic image, a stereodiagram, a model, or a computer-displayed image, at least a portion of the points derived from structure coordinates listed in Table 7, comprising a HGFA binding site, wherein the HGFA domain forms a crystal having the space group symmetry P21.

### Claim 13

A machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein a machine programmed with instructions for using such data displays a graphical three-dimensional representation of at least one molecule or molecular complex comprising at least a portion of a HGFA binding site, the binding site defined by a set of points having a root mean square deviation of less than about 0.05 Å from points representing the atoms of the amino acids as represented by the structure coordinates listed in Table 7 or 8.

### Claim 14

A machine readable data storage medium comprising data storage material encoded with a first set of machine readable data which is combined with a second set of machine readable data using a machine programmed with instructions for using the first and second sets of data, and which determines at least a portion of the structure coordinates corresponding to the second set of data, wherein the first set of data comprises a Fourier transform of at least a portion of the HGFA structural coordinates of Table 7 or 8, and wherein the second set of data comprises an X-ray diffraction pattern of a molecule or molecular complex for which the three dimensional structure is unknown or incompletely known.

### Claim 15

A molecule or molecular complex comprising at least a portion of a HGFA binding site for an inhibitor or substrate having an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2, wherein the binding site comprises at least one amino acid residue in a position of HGFA in a S1, S2, S3/4, S1′, S2′, S3′ subsite, or mixtures thereof, and the at least one amino acid residue is defined by a set of points have a root mean square deviation of less than 0.70 Å from points representing the backbone atoms of the amino acids as represented by the structural coordinates listed in Table 8.

### Claim 16 (depends on 15)

The molecule or molecular complex of claim 15, wherein the S1 subsite comprises at least one amino acid residue in a position of HGFA selected from the group consisting of 592(189), 593(190), 594(191), 595(192), 597(194), 616(213), 618 (215), 619(216), 620 (217), 621 (219), 622(220), 631(228), and mixtures thereof.

### Claim 17 (depends on 15)

The molecule or molecular complex of claim 15, wherein the S2 subsite comprises at least one amino acid residue in a position of HGFA selected from the group consisting of 447(57), 493(99a), 494(99), 497(102), and mixtures thereof.

### Claim 18 (depends on 15)

The molecule or molecular complex of claim 15, wherein the S3/4 subsite comprises at least one amino acid residue in a position of HGFA selected from the group consisting of 492(98), 493(99a), 494(99), 576(175), 581(180), 618(215), and mixtures thereof.

### Claim 19 (depends on 15)

The molecule or molecular complex of claim 15, wherein the S1′ subsite comprises at least one amino acid residue corresponding to the residue in a position of HGFA selected from the group consisting of 432(42), 447(57), 448(58), 598(195), and mixtures thereof.

### Claim 20 (depends on 15)

The molecule or molecular complex of claim 15, wherein the S2′ subsite comprises at least one amino acid residue in a position of HGFA selected from the group consisting of 430(40), 431(41), 542(143), 550(151), 595(192), 596(193), and mixtures thereof.

### Claim 21 (depends on 15)

The molecule or molecular complex of claim 15, wherein the S3′ subsite comprises at least one amino acid residue in a position of HGFA selected from the group consisting of 427 (35), 430(40), 432(42), 447(57), 448(58), 449(59), 451 (60a), and mixtures thereof.

### Claim 22

A molecule or molecular complex comprising at least a portion of a HGFA binding site for a substrate or inhibitor comprising a sequence of SEQ ID NO:1 or SEQ ID NO:2, wherein the binding site comprises at least one amino acid residue corresponding to an amino acid residue in a position of HGFA selected from the group consisting of 427(35), 430(40), 431(41), 432(42), 447(57), 448(58), 449(59), 451(60a), 492(98), 493(99a), 494(99), 497 (102), 542(143), 550 (151), 576 (175), 581(180), 592(189), 593(190), 594(191), 595(192), 596(193), 597(194), 598(195), 616(213), 618(215), 619(216), 621(219), 622(220), 631(228), and mixtures thereof, and the at least one amino acid residue is defined by a set of points having a mean square deviation of less than about 0.70 Å from points representing the backbone atoms of the amino acids as represented by the structure coordinates listed in Table 8.

### Claim at position 23

23-24. (canceled)

### Claim 25 (depends on 22)

The molecule or molecular complex of claim 22, wherein the at least one residue is in a position of HGFA selected from the group consisting of 429(39), 430(40), 431(41), 447(57), 448(58), 451(60a), 494(99), 548(149), 550(151), 592(189), 593(190), 595(192), 596(193), 597(194), 598(195), 617(214), 618(215), 619(216), 621(219), and mixtures thereof.

### Claim 26

A method for obtaining structural information about a molecule or molecular complex comprising application of at least a portion of the HGFA structure coordinates listed in Table 7 or 8 to an X-ray diffraction pattern of the molecule or molecular complex's crystal structure to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex.

### Claim 27 (depends on 26)

The method of claim 26, wherein the molecule or molecular complex comprises an antagonist of at least one biological activity of HGFA.

### Claim 28

A computer-assisted method for identifying an agent that modulates HGFA activity comprising:
(a) providing a computer modeling application with a set of structure coordinates of Table 7 or 8 defining at least a portion of a HGFA binding site;
(b) providing the computer modeling application with a set of structure coordinates for a test agent; and
(c) modeling the structure of (a) complexed with (b) to determine if the test agent associates with the HGFA binding site.

### Claim 29 (depends on 28)

The method of claim 28, wherein the binding site comprises at least one amino acid residue in a subsite of HGFA selected from the group consisting of S1, S2, S3/4, S1′, S2′, S3′, and mixtures thereof, of a polypeptide having an amino acid sequence of SEQ ID NO:2.

### Claim 30

A computer-assisted method for designing an agent that binds the HGFA binding site, comprising:
(a) providing a computer modeling application with a set of structural coordinates of Table 7 or 8 defining at least a portion of the HGFA binding site; and
(b) modeling the structural coordinates of (a) to identify an agent that contacts at least one amino acid residue in the HGFA binding site.

### Claim 31

A method of identifying a molecule that mimics HGFA comprising:
a) searching a molecular structure database with the structural coordinates of Table 7 or 8; and
b) selecting a molecule from the database that mimics the structural coordinates of the HGFA.

### Claim 32

A method of assessing agents that are antagonists or agonists of HGFA comprising:
a) applying at least a portion of the crystallography coordinates of Table 7 or 8 to a computer algorithm that generates a 3 dimensional model of HGFA suitable for designing molecules that are antagonists or agonists; and
b) searching a molecular structure database to identify potential antagonists or agonists of HGFA.

### Claim 33 (depends on 32)

The method of claim 32, further comprising:
a) synthesizing or obtaining the antagonist or agonist;
b) contacting the antagonist or agonist with HGFA and selecting the antagonist or agonist that modulates the activity of HGFA.

### Claim 34

(canceled)

### Claim 35

A method for evaluating the ability of a chemical agent to associate with a molecule or molecular complex comprising at least one amino acid residue in a subsite of HGFA binding site selected from the group consisting of S1, S2, S3/4, S1′, S2′, S3′, and mixtures thereof, said method comprising employing computational means to perform a fitting operation between the chemical agent and the structure coordinates of the amino acid residues of the binding site; and analyzing the results of the fitting operation and selecting those chemical agents that associate with the amino acid residue as defined by favorable polar, nonpolar, electrostatic, shape complementarity, or combinations thereof after conformational adjustments to the binding site.

### Claim 36 (depends on 32)

The method of claim 32, wherein the portion of the crystallography coordinates of Table 8 comprise at least one amino acid in a subsite selected from the group consisting of S1, S2, S3/4, S1′, S2′, S3′ subsites of the HGFA binding site, and mixtures thereof.

### Claim 37 (depends on 36)

The method of claim 36, wherein the structural coordinates of the amino acid residues of the S1 binding site are excluded.

### Claim 38 (depends on 36)

The method of claim 36, wherein the structural coordinates of the amino acid residues Asp215, Gly216, and Ser217 of HGFA are excluded.

### Claim 39

(canceled)

### Claim 40

A peptide consisting of an amino acid sequence starting at position 256 and ending at position 284 of a polypeptide having a sequence of SEQ ID NO:3 or SEQ ID NO:4.

### Claim 41

A three-dimensional configuration of points, at least a portion of the points derived from structure coordinates listed in Table 8, comprising a HGFA binding site for an inhibitor, wherein the HGFA forms a crystal having the space group symmetry P3121.

### Claim 42 (depends on 41)

The three-dimensional configuration of points of any of claim 41 displayed as a holographic image, a stereodiagram, a model, or a computer-displayed image, at least a portion of the points derived from structure coordinates listed in Table 8, comprising a HGFA active site, wherein the HGFA domain forms a crystal having the space group symmetry P3121.

### Claim 43

A machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein a machine programmed with instructions for using such data displays a graphical three-dimensional representation of at least one molecule or molecular complex comprising at least a portion of a HGFA binding site or or an inhibitor or substrate, the binding site defined by a set of points having a root mean square deviation of less than about 0.05 Å from points representing the atoms of the amino acids as represented by the structure coordinates listed in Table 8.

### Claim 44

A crystal of hepatocyte growth factor activator (HGFA) complexed with a Kunitz domain inhibitor comprising a human hepatocyte growth factor activator comprising SEQ ID NO:2 complexed with a Kunitz domain inhibitor comprising SEQ ID NO:4.

### Claim 45

(canceled)

### Claim 46 (depends on 44)

A crystal of claim 44 of a 1:1 complex of the HGFA with a fragment of the Kunitz domain inhibitor having a space group symmetry of P3121 and comprising a unit cell having the dimensions of a, b, and c, where a and b are about 76.22 Å, and c is about 176.24 Å.

### Claim 47 (depends on 44)

A crystal of HGFA with a fragment of the Kunitz domain inhibitor of claim 44 having the three-dimensional coordinates of Table 8.

### Claim 48 (depends on 44)

A composition comprising a crystal of claim 44, and a carrier.

### Claim 49 (depends on 48)

The composition of claim 48, wherein the HGFA or KD1, or both, are biologically active when resolubilized.

### Claim 50 (depends on 44)

A heavy atom derivative of a crystallized form of HGFA:KD1 of claim 44.

### Claim 51

(canceled)

### Claim 52 (depends on 41)

A three-dimensional configuration of points according to claim 41, at least a portion of the points derived from structure coordinates listed in Table 8, comprising a HGFA binding site for KD1, wherein the HGFA:KD1 forms a crystal having the space group symmetry P3121.

### Claim 53 (depends on 52)

The three-dimensional configuration of points of claim 52, wherein substantially all of the points are derived from structure coordinates listed in Table 8.

### Claim 54 (depends on 53)

The three-dimensional configuration of points of claim 53, wherein at least a portion of the points are derived from structure coordinates representing locations of at least the backbone atoms of amino acids defining the HGFA binding site for KD1.

### Claim 55

A computer assisted method for identifying an agent that modulates HGFA activity comprising:
a) modifying of at least one amino acid residue in a HGFA binding site on a Kunitz domain inhibitor;
b) performing a fitting operation between the modified Kunitz domain inhibitor and the structural coordinates of at least one amino acid residue of a HGFA binding site for KD1 as set forth in Table 8.

### Claim 56

A method of inhibiting HGFA in a cell comprising contacting the cell with a fragment of a Kunitz domain inhibitor comprising an amino acid sequence corresponding to amino acid sequence of amino acid 256 to 284 of a polypeptide having a sequence of SEQ ID NO:3, SEQ ID NO:4, an amino acid sequence Val-Arg-Cys-Arg-Xaa-Ser-Phe (SEQ ID NO:5), wherein Xaa is Gly, Ala, or Ser, or an amino acid sequence Val-Gly-Arg-Cys-Arg-Xaa-Ser-Phe, wherein Xaa is Gly, Ala, or Ser (SEQ ID NO:8).

### Claim 57

A fragment of HGFA comprising an amino acid sequence starting from any amino acid located at position 373 to amino acid 408 and ending at amino acid residue 655.

### Claim 58

A fragment of a Kunitz domain inhibitor comprising an amino acid sequence of SEQ ID NO:4.

### Claim 59

A peptide inhibitor of HGFA comprising an amino acid sequence Val-Arg-Cys-Arg-Xaa-Ser-Phe (SEQ ID NO:5).

### Claim 60

A molecule or molecular complex comprising at least a portion of a HGFA binding site for an inhibitor, wherein HGFA comprises a sequence of SEQ ID NO:1 or SEQ ID NO:2, wherein the binding site comprises at least one amino acid residue corresponding to an amino acid residue in a position of HGFA selected from the group consisting His447(57), Ser450(60), His451(60a), Pro493(99a), Ser494(99), Asp497(102), Asp592(189), Ala593(190), Cys594(191), Gln595(192), Ser598(195), Ile616(213), Ser617(214), Trp618(215), Gly619(216), Asp620(217), Gly621(219), Cys622(220), Gly629(226), and mixtures thereof, wherein the at least one amino acid residue is defined by a set of points having a root mean sequence deviation of about 0.70 Å or less from points representing the backbone of the amino acids as represented by the structural coordinates in Table 8.
